Another real‐world study of advanced EGFR‐mutated NSCLC showed that combination therapy with an first‐line EGFR‐TKI and bevacizumab resulted in the objective response rate of 77.8%, disease control rate of 94.4%, and median PFS of 16.4 months; in terms of the type of EGFR TKI, patients taking erlotinib had similar PFS compared to those taking afatinib (median PFS: 17.1 vs. 21.6 months, p = 0.217).31 This evidence concerns the gene EGFR and non-small cell lung carcinoma.